Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Safety and Efficacy Evaluation of Enhanced Autologous PSMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Castration Resistant Prostate Cancer

Next Previous
Trial Profile

The Safety and Efficacy Evaluation of Enhanced Autologous PSMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Castration Resistant Prostate Cancer

Status: Recruiting
Phase of Trial: Phase 0

Latest Information Update: 24 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti PSMA chimeric antigen receptor T cell therapy BRL Medicine (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Sponsors BRL Medicine

Most Recent Events

  • 24 Apr 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
  • 05 Feb 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top